Results 51 to 60 of about 16,563 (220)

Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer

Advanced Science, EarlyView.
RT promotes VG161 replication in BC and its immunostimulatory transgenes expression, which is mediated by the upregulation of GADD34 and HVEM caused by RT. The combination therapy with VG161 and RT increases the abundances of tumor‐infiltrating lymphocytes and elicits potent systemic antitumor immunity, thereby effectively inhibiting local tumors and ...
Lijuan Lyu, Ming Yi, Ji Chen, Zeda Zhao, Ruocen Liao, Yingnan Wang, Shengtao Hu, Jun Ding, Ronghua Zhao, William Jia, Yinan Shen, Yongchang Wei, Kongming Wu, Zhijun Dai   +13 more
wiley   +1 more source

Targeting KDM3B Elicits Anti‐tumor Immunity by Alleviating SHP1–mediated STING Suppression in Triple–Negative Breast Cancer

Advanced Science, EarlyView.
P3FI–90 treatment targets KDM3B, reshapes the epigenetic landscape, and suppresses SHP1 expression, thereby activating STING–TBK1–IRF3–type I IFN signaling pathway. Consequently, CD8+ T cells are recruited to the tumor site and activated to produce IFN–γ and GZMB, leading to the killing of TNBC cells.
Xiaolong Wang, Wenhao Li, Yifei Wang, Ning Zhang, Bing Chen, Wenjing Zhao, Lijuan Wang, Dan Luo, Qifeng Yang   +8 more
wiley   +1 more source

Is nab-paclitaxel better than conventional taxanes as neoadjuvant therapy for breast cancer? A meta-analysis

Journal of International Medical Research, 2020
Objective This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with conventional taxanes as neoadjuvant chemotherapy for breast cancer. Methods We searched the literature using PubMed, the Cochrane Library,
Yong Li, Xiaoju Lu, Qimou Lin, Weiwen Li
doaj   +1 more source

FOS3D: A Fluorescence‐Enabled Toolkit for Characterizing a Three‐dimensional Osteosarcoma Model

Advanced Science, EarlyView.
FOS3D describes fluorescent (F) osteosarcoma (OS) cells in a tri‐dimensional (3D) model. The study comprises three phases: development, where biofabrication parameters are tuned to achieve cytocompatibility and tumor‐specific mechanical properties in cell‐laden gelatin methacryloyl constructs; validation, where whole‐well fluorescence reading is ...
William Humble, Wiktor Zywicki, Enrico Lucarelli, Ania Naila Guerrieri, Francesca Taraballi, Gianluca Cidonio, Claudia Di Bella, Carmine Onofrillo, Andrea J. O'Connor, Serena Duchi   +9 more
wiley   +1 more source

Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks

Scientific Reports
Nab-paclitaxel (albumin-bound paclitaxel) and traditional paclitaxel are both used in pancreatic cancer treatment, but their adverse event (AE) profiles may differ due to formulation differences.
Nan Qin, Zhongliu Bian, Jingtao Chen
doaj   +1 more source

Delayed hypersensitivity and cytokine release syndrome to paclitaxel and nab-paclitaxel: a case report [PDF]

Exploration of Asthma & Allergy
Hypersensitivity reactions (HSRs) to paclitaxel, particularly those mediated by the solubilizer Cremophor® EL, are common, occurring in approximately 10% of patients despite premedication.
Shaonie Ton-Leclerc, Florian Stehlin, Ana Maria Copaescu, Ghislaine Isabwe   +3 more
doaj   +1 more source

A Biomimetic Dual‐Targeting Nano‐APA‐Editor Reprograms the 3'UTR Landscape for Tongue Squamous Cell Carcinoma Therapy

Advanced Science, EarlyView.
This study unveils a pathogenic axis in oral cancer where NUDT21 suppresses a tumor suppressor network, prominently PTEN, via 3'UTR lengthening. To exploit this transcriptomic vulnerability, we developed a biomimetic Nano‐APA‐editor. By delivering CRISPR/Cas9, we reprogrammed the global 3'UTR landscape, restoring multi‐target tumor suppression and ...
Yiran Ao, Bin Gu, Hui Zhao, Kun Tan, Qin Zhao, Zhengjun Shang   +5 more
wiley   +1 more source

A five arm natural history study of nasal vestibulitis

Cancer Medicine, 2023
Introduction Nasal symptoms are frequently reported by patients undergoing chemotherapy. Methods Eligible patients planning to receive paclitaxel, docetaxel, nab‐paclitaxel, bevacizumab without a concomitant taxane, or “other” (non‐taxane, non ...
Elizabeth J. Cathcart‐Rake, David Zahrieh, Deanne Smith, Susan Young, Shaylene McCue, Amanda O'Connor, Stephan Thomé, Mario Lacouture, Terra Register, Jill Piens, Bret B. Friday, Charles L. Loprinzi   +11 more
doaj   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong, Ximo Xu, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long   +13 more
wiley   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source